| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | retinoic acid 4-hydroxylase activity | 1.79e-07 | 14 | 75 | 4 | GO:0008401 | |
| GeneOntologyMolecularFunction | linoleic acid epoxygenase activity | 2.03e-07 | 4 | 75 | 3 | GO:0071614 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 1.09e-06 | 49 | 75 | 5 | GO:0016712 | |
| GeneOntologyMolecularFunction | arachidonate epoxygenase activity | 1.84e-06 | 24 | 75 | 4 | GO:0008392 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor | 2.81e-06 | 8 | 75 | 3 | GO:0033695 | |
| GeneOntologyMolecularFunction | caffeine oxidase activity | 2.81e-06 | 8 | 75 | 3 | GO:0034875 | |
| GeneOntologyMolecularFunction | arachidonate monooxygenase activity | 3.02e-06 | 27 | 75 | 4 | GO:0008391 | |
| GeneOntologyMolecularFunction | estrogen 16-alpha-hydroxylase activity | 8.22e-06 | 11 | 75 | 3 | GO:0101020 | |
| GeneOntologyMolecularFunction | aromatase activity | 8.80e-06 | 35 | 75 | 4 | GO:0070330 | |
| GeneOntologyMolecularFunction | (R)-limonene 6-monooxygenase activity | 1.39e-05 | 2 | 75 | 2 | GO:0052741 | |
| GeneOntologyMolecularFunction | (S)-limonene 6-monooxygenase activity | 1.39e-05 | 2 | 75 | 2 | GO:0018675 | |
| GeneOntologyMolecularFunction | (S)-limonene 7-monooxygenase activity | 1.39e-05 | 2 | 75 | 2 | GO:0018676 | |
| GeneOntologyMolecularFunction | cysteine-S-conjugate N-acetyltransferase activity | 1.39e-05 | 2 | 75 | 2 | GO:0047198 | |
| GeneOntologyMolecularFunction | limonene monooxygenase activity | 1.39e-05 | 2 | 75 | 2 | GO:0019113 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on CH or CH2 groups | 2.24e-05 | 15 | 75 | 3 | GO:0016725 | |
| GeneOntologyMolecularFunction | monooxygenase activity | 7.27e-05 | 115 | 75 | 5 | GO:0004497 | |
| GeneOntologyMolecularFunction | arachidonate 11,12-epoxygenase activity | 8.31e-05 | 4 | 75 | 2 | GO:0008405 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 8.98e-05 | 194 | 75 | 6 | GO:0016705 | |
| GeneOntologyMolecularFunction | fatty acid omega-1 hydroxylase activity | 1.38e-04 | 5 | 75 | 2 | GO:0120502 | |
| GeneOntologyMolecularFunction | long-chain fatty acid omega-1 hydroxylase activity | 1.38e-04 | 5 | 75 | 2 | GO:0120319 | |
| GeneOntologyMolecularFunction | arachidonate 14,15-epoxygenase activity | 1.38e-04 | 5 | 75 | 2 | GO:0008404 | |
| GeneOntologyMolecularFunction | mRNA 3'-UTR AU-rich region binding | 1.73e-04 | 29 | 75 | 3 | GO:0035925 | |
| GeneOntologyMolecularFunction | lysine N-acetyltransferase activity, acting on acetyl phosphate as donor | 2.07e-04 | 6 | 75 | 2 | GO:0004468 | |
| GeneOntologyMolecularFunction | steroid hydroxylase activity | 2.80e-04 | 34 | 75 | 3 | GO:0008395 | |
| GeneOntologyMolecularFunction | heme binding | 2.86e-04 | 154 | 75 | 5 | GO:0020037 | |
| GeneOntologyMolecularFunction | vascular endothelial growth factor receptor activity | 2.89e-04 | 7 | 75 | 2 | GO:0005021 | |
| GeneOntologyMolecularFunction | tetrapyrrole binding | 3.82e-04 | 164 | 75 | 5 | GO:0046906 | |
| GeneOntologyMolecularFunction | iron ion binding | 4.03e-04 | 166 | 75 | 5 | GO:0005506 | |
| GeneOntologyMolecularFunction | mismatched DNA binding | 1.23e-03 | 14 | 75 | 2 | GO:0030983 | |
| GeneOntologyMolecularFunction | transmembrane receptor protein tyrosine kinase activity | 1.88e-03 | 65 | 75 | 3 | GO:0004714 | |
| GeneOntologyMolecularFunction | basal RNA polymerase II transcription machinery binding | 1.97e-03 | 66 | 75 | 3 | GO:0001099 | |
| GeneOntologyMolecularFunction | basal transcription machinery binding | 1.97e-03 | 66 | 75 | 3 | GO:0001098 | |
| GeneOntologyMolecularFunction | SUMO ligase activity | 2.53e-03 | 20 | 75 | 2 | GO:0061665 | |
| GeneOntologyMolecularFunction | ATP-dependent DNA damage sensor activity | 2.53e-03 | 20 | 75 | 2 | GO:0140664 | |
| GeneOntologyMolecularFunction | DNA damage sensor activity | 3.64e-03 | 24 | 75 | 2 | GO:0140612 | |
| GeneOntologyMolecularFunction | transmembrane receptor protein kinase activity | 4.03e-03 | 85 | 75 | 3 | GO:0019199 | |
| GeneOntologyMolecularFunction | RNA polymerase II general transcription initiation factor binding | 4.60e-03 | 27 | 75 | 2 | GO:0001091 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 4.79e-03 | 417 | 75 | 6 | GO:0061629 | |
| GeneOntologyBiologicalProcess | omega-hydroxylase P450 pathway | 1.57e-07 | 14 | 75 | 4 | GO:0097267 | |
| GeneOntologyBiologicalProcess | epoxygenase P450 pathway | 1.12e-06 | 22 | 75 | 4 | GO:0019373 | |
| GeneOntologyBiologicalProcess | arachidonate metabolic process | 4.84e-06 | 68 | 75 | 5 | GO:0019369 | |
| GeneOntologyBiologicalProcess | peptidyl-lysine N6-acetylation | 1.30e-05 | 2 | 75 | 2 | GO:0018003 | |
| GeneOntologyBiologicalProcess | icosanoid metabolic process | 1.31e-05 | 142 | 75 | 6 | GO:0006690 | |
| GeneOntologyBiologicalProcess | linoleic acid metabolic process | 7.76e-05 | 23 | 75 | 3 | GO:0043651 | |
| GeneOntologyBiologicalProcess | long-chain fatty acid metabolic process | 8.93e-05 | 124 | 75 | 5 | GO:0001676 | |
| GeneOntologyBiologicalProcess | unsaturated fatty acid metabolic process | 1.04e-04 | 128 | 75 | 5 | GO:0033559 | |
| GeneOntologyBiologicalProcess | response to 2,3,7,8-tetrachlorodibenzodioxine | 1.30e-04 | 5 | 75 | 2 | GO:1904612 | |
| GeneOntologyBiologicalProcess | xenobiotic metabolic process | 1.63e-04 | 141 | 75 | 5 | GO:0006805 | |
| GeneOntologyBiologicalProcess | monoterpenoid metabolic process | 1.94e-04 | 6 | 75 | 2 | GO:0016098 | |
| GeneOntologyCellularComponent | late recombination nodule | 4.44e-08 | 3 | 75 | 3 | GO:0005715 | |
| GeneOntologyCellularComponent | recombination nodule | 1.77e-07 | 4 | 75 | 3 | GO:0005713 | |
| GeneOntologyCellularComponent | chiasma | 1.27e-05 | 2 | 75 | 2 | GO:0005712 | |
| GeneOntologyCellularComponent | nuclear stress granule | 1.89e-04 | 6 | 75 | 2 | GO:0097165 | |
| GeneOntologyCellularComponent | condensed nuclear chromosome | 3.23e-04 | 91 | 75 | 4 | GO:0000794 | |
| GeneOntologyCellularComponent | cytoplasmic periphery of the nuclear pore complex | 3.51e-04 | 8 | 75 | 2 | GO:1990723 | |
| GeneOntologyCellularComponent | nuclear pore cytoplasmic filaments | 5.61e-04 | 10 | 75 | 2 | GO:0044614 | |
| GeneOntologyCellularComponent | mismatch repair complex | 6.84e-04 | 11 | 75 | 2 | GO:0032300 | |
| GeneOntologyCellularComponent | nuclear outer membrane-endoplasmic reticulum membrane network | AKAP6 RGPD4 NAT8B CYP2C19 CYP2C8 CYP2C9 ERLIN2 CYP2C18 RGPD3 NAT8 ATL3 SEL1L2 SORL1 | 8.11e-04 | 1327 | 75 | 13 | GO:0042175 |
| GeneOntologyCellularComponent | annulate lamellae | 1.12e-03 | 14 | 75 | 2 | GO:0005642 | |
| GeneOntologyCellularComponent | nuclear pore nuclear basket | 1.87e-03 | 18 | 75 | 2 | GO:0044615 | |
| GeneOntologyCellularComponent | nuclear chromosome | 2.20e-03 | 254 | 75 | 5 | GO:0000228 | |
| GeneOntologyCellularComponent | nuclear inclusion body | 2.31e-03 | 20 | 75 | 2 | GO:0042405 | |
| GeneOntologyCellularComponent | SUMO ligase complex | 2.55e-03 | 21 | 75 | 2 | GO:0106068 | |
| Domain | ELAD_HUD_SF | 2.19e-07 | 4 | 72 | 3 | IPR006548 | |
| Domain | Hud_Sxl_RNA | 6.47e-06 | 10 | 72 | 3 | IPR002343 | |
| Domain | Cyt_P450_E_grp-I | 2.68e-05 | 45 | 72 | 4 | IPR002401 | |
| Domain | DNA_mis_repair | 4.39e-05 | 3 | 72 | 2 | SM01340 | |
| Domain | Cyt_P450_CS | 5.15e-05 | 53 | 72 | 4 | IPR017972 | |
| Domain | CYTOCHROME_P450 | 6.87e-05 | 57 | 72 | 4 | PS00086 | |
| Domain | - | 7.36e-05 | 58 | 72 | 4 | 1.10.630.10 | |
| Domain | p450 | 7.36e-05 | 58 | 72 | 4 | PF00067 | |
| Domain | Cyt_P450 | 8.41e-05 | 60 | 72 | 4 | IPR001128 | |
| Domain | DNA_mismatch_repair_C | 8.75e-05 | 4 | 72 | 2 | IPR013507 | |
| Domain | DNA_mismatch_repair_fam | 8.75e-05 | 4 | 72 | 2 | IPR002099 | |
| Domain | DNA_mis_repair | 8.75e-05 | 4 | 72 | 2 | PF01119 | |
| Domain | DNA_MISMATCH_REPAIR_1 | 8.75e-05 | 4 | 72 | 2 | PS00058 | |
| Domain | DNA_mismatch_repair_CS | 1.45e-04 | 5 | 72 | 2 | IPR014762 | |
| Domain | GCC2_Rab_bind | 3.04e-04 | 7 | 72 | 2 | IPR032023 | |
| Domain | Rab_bind | 3.04e-04 | 7 | 72 | 2 | PF16704 | |
| Domain | - | 6.46e-04 | 10 | 72 | 2 | 1.10.220.60 | |
| Domain | Grip | 7.88e-04 | 11 | 72 | 2 | SM00755 | |
| Domain | GRIP | 7.88e-04 | 11 | 72 | 2 | PF01465 | |
| Domain | Ran_BP1 | 9.43e-04 | 12 | 72 | 2 | PF00638 | |
| Domain | GRIP_dom | 9.43e-04 | 12 | 72 | 2 | IPR000237 | |
| Domain | GRIP | 9.43e-04 | 12 | 72 | 2 | PS50913 | |
| Domain | RANBD1 | 9.43e-04 | 12 | 72 | 2 | PS50196 | |
| Domain | RanBD | 1.11e-03 | 13 | 72 | 2 | SM00160 | |
| Domain | Ran_bind_dom | 1.11e-03 | 13 | 72 | 2 | IPR000156 | |
| Domain | HATPase_c | 2.15e-03 | 18 | 72 | 2 | SM00387 | |
| Domain | HATPase_c | 2.40e-03 | 19 | 72 | 2 | PF02518 | |
| Domain | - | 2.66e-03 | 20 | 72 | 2 | 3.30.565.10 | |
| Domain | - | 2.94e-03 | 21 | 72 | 2 | 3.30.230.10 | |
| Domain | HATPase_C | 2.94e-03 | 21 | 72 | 2 | IPR003594 | |
| Domain | Ribosomal_S5_D2-typ_fold_subgr | 3.22e-03 | 22 | 72 | 2 | IPR014721 | |
| Domain | RRM_dom_euk | 3.52e-03 | 23 | 72 | 2 | IPR003954 | |
| Domain | Acetyltransf_1 | 3.52e-03 | 23 | 72 | 2 | PF00583 | |
| Domain | RRM_1 | 3.52e-03 | 23 | 72 | 2 | SM00361 | |
| Domain | GNAT | 4.15e-03 | 25 | 72 | 2 | PS51186 | |
| Domain | GNAT_dom | 4.15e-03 | 25 | 72 | 2 | IPR000182 | |
| Domain | Galactose-bd-like | 5.73e-03 | 94 | 72 | 3 | IPR008979 | |
| Domain | Ribosomal_S5_D2-typ_fold | 7.59e-03 | 34 | 72 | 2 | IPR020568 | |
| Pathway | REACTOME_XENOBIOTICS | 2.63e-08 | 23 | 56 | 5 | M5372 | |
| Pathway | REACTOME_XENOBIOTICS | 2.65e-06 | 25 | 56 | 4 | MM14846 | |
| Pathway | REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET | 3.28e-06 | 8 | 56 | 3 | M27135 | |
| Pathway | REACTOME_SYNTHESIS_OF_16_20_HYDROXYEICOSATETRAENOIC_ACIDS_HETE | 4.90e-06 | 9 | 56 | 3 | M27143 | |
| Pathway | KEGG_LINOLEIC_ACID_METABOLISM | 4.93e-06 | 29 | 56 | 4 | M2920 | |
| Pathway | REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE | 5.26e-06 | 64 | 56 | 5 | M5650 | |
| Pathway | REACTOME_CYP2E1_REACTIONS | 9.58e-06 | 11 | 56 | 3 | M27130 | |
| Pathway | WP_OCTADECANOID_FORMATION_FROM_LINOLEIC_ACID | 1.27e-05 | 12 | 56 | 3 | M48064 | |
| Pathway | WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES | 2.10e-05 | 14 | 56 | 3 | MM15842 | |
| Pathway | REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS | 5.62e-05 | 104 | 56 | 5 | M738 | |
| Pathway | WP_TAMOXIFEN_METABOLISM | 7.51e-05 | 21 | 56 | 3 | M39631 | |
| Pathway | KEGG_ARACHIDONIC_ACID_METABOLISM | 8.08e-05 | 58 | 56 | 4 | M5410 | |
| Pathway | WP_OXIDATION_BY_CYTOCHROME_P450 | 1.05e-04 | 62 | 56 | 4 | M39653 | |
| Pathway | WP_ESTROGEN_METABOLISM_WP5276 | 1.13e-04 | 24 | 56 | 3 | M46445 | |
| Pathway | KEGG_RETINOL_METABOLISM | 1.19e-04 | 64 | 56 | 4 | M9488 | |
| Pathway | REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE | 1.34e-04 | 66 | 56 | 4 | MM14839 | |
| Pathway | KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 | 1.69e-04 | 70 | 56 | 4 | M16794 | |
| Pathway | KEGG_DRUG_METABOLISM_CYTOCHROME_P450 | 1.88e-04 | 72 | 56 | 4 | M9257 | |
| Pathway | WP_CANNABINOID_RECEPTOR_SIGNALING | 2.02e-04 | 29 | 56 | 3 | M39676 | |
| Pathway | REACTOME_BIOSYNTHESIS_OF_MARESIN_LIKE_SPMS | 2.30e-04 | 6 | 56 | 2 | M27909 | |
| Pathway | WP_ARACHIDONATE_EPOXYGENASE_EPOXIDE_HYDROLASE | 3.21e-04 | 7 | 56 | 2 | M39515 | |
| Pathway | REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET | 3.21e-04 | 7 | 56 | 2 | MM14856 | |
| Pathway | REACTOME_BIOSYNTHESIS_OF_MARESINS | 4.27e-04 | 8 | 56 | 2 | M27891 | |
| Pathway | REACTOME_NUCLEAR_PORE_COMPLEX_NPC_DISASSEMBLY | 5.29e-04 | 40 | 56 | 3 | MM14945 | |
| Pathway | WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES_PATHWAY | 5.48e-04 | 9 | 56 | 2 | M39819 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_SMALL_RNAS | 5.69e-04 | 41 | 56 | 3 | MM15200 | |
| Pathway | REACTOME_SUMOYLATION_OF_SUMOYLATION_PROTEINS | 6.11e-04 | 42 | 56 | 3 | MM15039 | |
| Pathway | REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA | 6.55e-04 | 43 | 56 | 3 | MM14609 | |
| Pathway | REACTOME_ASPIRIN_ADME | 7.01e-04 | 44 | 56 | 3 | M45014 | |
| Pathway | WP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II | 7.80e-04 | 183 | 56 | 5 | M39588 | |
| Pathway | REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS | 7.93e-04 | 105 | 56 | 4 | MM14842 | |
| Pathway | REACTOME_SYNTHESIS_OF_16_20_HYDROXYEICOSATETRAENOIC_ACIDS_HETE | 8.33e-04 | 11 | 56 | 2 | MM14863 | |
| Pathway | REACTOME_SUMOYLATION_OF_UBIQUITINYLATION_PROTEINS | 8.51e-04 | 47 | 56 | 3 | MM14939 | |
| Pathway | REACTOME_GENE_SILENCING_BY_RNA | 9.61e-04 | 49 | 56 | 3 | MM14837 | |
| Pathway | REACTOME_SEPARATION_OF_SISTER_CHROMATIDS | 9.91e-04 | 193 | 56 | 5 | MM14890 | |
| Pathway | REACTOME_CYP2E1_REACTIONS | 9.97e-04 | 12 | 56 | 2 | MM14847 | |
| Pathway | REACTOME_BIOSYNTHESIS_OF_MARESINS | 9.97e-04 | 12 | 56 | 2 | MM15616 | |
| Pathway | REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS | 1.02e-03 | 50 | 56 | 3 | MM14610 | |
| Pathway | REACTOME_SUMOYLATION_OF_DNA_REPLICATION_PROTEINS | 1.08e-03 | 51 | 56 | 3 | MM15151 | |
| Pathway | REACTOME_MITOTIC_SPINDLE_CHECKPOINT | 1.19e-03 | 117 | 56 | 4 | MM15387 | |
| Pathway | KEGG_LYSOSOME | 1.34e-03 | 121 | 56 | 4 | M11266 | |
| Pathway | REACTOME_NUCLEAR_ENVELOPE_BREAKDOWN | 1.35e-03 | 55 | 56 | 3 | MM14917 | |
| Pathway | REACTOME_SUMOYLATION_OF_RNA_BINDING_PROTEINS | 1.57e-03 | 58 | 56 | 3 | MM15149 | |
| Pathway | REACTOME_SNRNP_ASSEMBLY | 1.57e-03 | 58 | 56 | 3 | MM14736 | |
| Pathway | REACTOME_ARACHIDONIC_ACID_METABOLISM | 1.65e-03 | 59 | 56 | 3 | M27140 | |
| Pathway | REACTOME_BIOLOGICAL_OXIDATIONS | 1.77e-03 | 220 | 56 | 5 | M10320 | |
| Pathway | REACTOME_SUMOYLATION_OF_CHROMATIN_ORGANIZATION_PROTEINS | 2.18e-03 | 65 | 56 | 3 | MM15147 | |
| Pathway | BIOCARTA_RANBP2_PATHWAY | 2.28e-03 | 18 | 56 | 2 | MM1549 | |
| Pathway | REACTOME_MITOTIC_METAPHASE_AND_ANAPHASE | 2.32e-03 | 234 | 56 | 5 | MM14898 | |
| Pathway | REACTOME_SIGNAL_TRANSDUCTION_BY_L1 | 2.54e-03 | 19 | 56 | 2 | MM15113 | |
| Pathway | REACTOME_BIOSYNTHESIS_OF_SPECIALIZED_PRORESOLVING_MEDIATORS_SPMS | 2.54e-03 | 19 | 56 | 2 | M27889 | |
| Pubmed | Biochemistry and molecular biology of the human CYP2C subfamily. | 2.22e-11 | 4 | 77 | 4 | 7704034 | |
| Pubmed | 2.22e-11 | 4 | 77 | 4 | 19706858 | ||
| Pubmed | 2.22e-11 | 4 | 77 | 4 | 2009263 | ||
| Pubmed | 2.22e-11 | 4 | 77 | 4 | 21798861 | ||
| Pubmed | 2.22e-11 | 4 | 77 | 4 | 23755828 | ||
| Pubmed | The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. | 1.04e-08 | 3 | 77 | 3 | 10704292 | |
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 35134542 | ||
| Pubmed | Distribution of CYP2C polymorphisms in an Amerindian population of Brazil. | 1.04e-08 | 3 | 77 | 3 | 21977947 | |
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 23118231 | ||
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 28687336 | ||
| Pubmed | A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. | 1.04e-08 | 3 | 77 | 3 | 8530044 | |
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 21173785 | ||
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 15102943 | ||
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 1119809 | ||
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 24430292 | ||
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 20665013 | ||
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 27803446 | ||
| Pubmed | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. | 1.04e-08 | 3 | 77 | 3 | 19954515 | |
| Pubmed | 1.04e-08 | 3 | 77 | 3 | 8095407 | ||
| Pubmed | 2.19e-08 | 14 | 77 | 4 | 24553115 | ||
| Pubmed | Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population. | 2.19e-08 | 14 | 77 | 4 | 19290787 | |
| Pubmed | Association of warfarin dose with genes involved in its action and metabolism. | 3.96e-08 | 16 | 77 | 4 | 17048007 | |
| Pubmed | 4.17e-08 | 4 | 77 | 3 | 10848602 | ||
| Pubmed | 4.17e-08 | 4 | 77 | 3 | 28990182 | ||
| Pubmed | Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. | 4.17e-08 | 4 | 77 | 3 | 16025294 | |
| Pubmed | 4.17e-08 | 4 | 77 | 3 | 21808035 | ||
| Pubmed | 1.04e-07 | 5 | 77 | 3 | 19415824 | ||
| Pubmed | Prevalence of CYP450 gene variations in patients with type 2 diabetes. | 1.04e-07 | 5 | 77 | 3 | 20857895 | |
| Pubmed | Molecular genetics of the human cytochrome P450 monooxygenase superfamily. | 1.05e-07 | 20 | 77 | 4 | 9890157 | |
| Pubmed | Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. | 2.08e-07 | 6 | 77 | 3 | 17635176 | |
| Pubmed | A genome-wide association study of acenocoumarol maintenance dosage. | 2.08e-07 | 6 | 77 | 3 | 19578179 | |
| Pubmed | A hierarchy of Hu RNA binding proteins in developing and adult neurons. | 2.08e-07 | 6 | 77 | 3 | 9096138 | |
| Pubmed | Stabilization of Dll1 mRNA by Elavl1/HuR in neuroepithelial cells undergoing mitosis. | 3.63e-07 | 7 | 77 | 3 | 21346194 | |
| Pubmed | 3.63e-07 | 7 | 77 | 3 | 38000026 | ||
| Pubmed | 5.82e-07 | 30 | 77 | 4 | 20529763 | ||
| Pubmed | 1.24e-06 | 10 | 77 | 3 | 20602612 | ||
| Pubmed | 1.24e-06 | 10 | 77 | 3 | 19651758 | ||
| Pubmed | Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. | 1.70e-06 | 11 | 77 | 3 | 15469410 | |
| Pubmed | 1.70e-06 | 11 | 77 | 3 | 15039299 | ||
| Pubmed | 2.26e-06 | 12 | 77 | 3 | 15319333 | ||
| Pubmed | 2.57e-06 | 43 | 77 | 4 | 18510611 | ||
| Pubmed | 2.99e-06 | 179 | 77 | 6 | 19074885 | ||
| Pubmed | 3.73e-06 | 14 | 77 | 3 | 20970553 | ||
| Pubmed | Tet1 controls meiosis by regulating meiotic gene expression. | 3.73e-06 | 14 | 77 | 3 | 23151479 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 7574697 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 25301944 | ||
| Pubmed | Human MutLγ, the MLH1-MLH3 heterodimer, is an endonuclease that promotes DNA expansion. | 4.84e-06 | 2 | 77 | 2 | 32015124 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 30562214 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 26122864 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 10079173 | ||
| Pubmed | Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. | 4.84e-06 | 2 | 77 | 2 | 12435384 | |
| Pubmed | Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. | 4.84e-06 | 2 | 77 | 2 | 18511451 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 18694831 | ||
| Pubmed | Developmental expression of human hepatic CYP2C9 and CYP2C19. | 4.84e-06 | 2 | 77 | 2 | 14634042 | |
| Pubmed | CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. | 4.84e-06 | 2 | 77 | 2 | 10908295 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 1847130 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 28513222 | ||
| Pubmed | Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes. | 4.84e-06 | 2 | 77 | 2 | 17599801 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19038035 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 15385837 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 25518510 | ||
| Pubmed | Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. | 4.84e-06 | 2 | 77 | 2 | 8333835 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 16372821 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 15842554 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19136640 | ||
| Pubmed | Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage. | 4.84e-06 | 2 | 77 | 2 | 35748067 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 20890775 | ||
| Pubmed | Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development. | 4.84e-06 | 2 | 77 | 2 | 32587777 | |
| Pubmed | Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. | 4.84e-06 | 2 | 77 | 2 | 17201743 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 32683556 | ||
| Pubmed | Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. | 4.84e-06 | 2 | 77 | 2 | 18548238 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 15855721 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19847408 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 17504998 | ||
| Pubmed | Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. | 4.84e-06 | 2 | 77 | 2 | 24519941 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 14623888 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 27089381 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 24204323 | ||
| Pubmed | Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. | 4.84e-06 | 2 | 77 | 2 | 14646690 | |
| Pubmed | Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. | 4.84e-06 | 2 | 77 | 2 | 10487415 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19480553 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 22589111 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 9763509 | ||
| Pubmed | CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. | 4.84e-06 | 2 | 77 | 2 | 15660966 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 18154472 | ||
| Pubmed | Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. | 4.84e-06 | 2 | 77 | 2 | 15766564 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 27353638 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 17298483 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 33115391 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 21047199 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 17562299 | ||
| Pubmed | Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. | 4.84e-06 | 2 | 77 | 2 | 16646575 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 36960518 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 26690534 | ||
| Pubmed | cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. | 4.84e-06 | 2 | 77 | 2 | 3697070 | |
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19199010 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19381162 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 19358898 | ||
| Pubmed | 4.84e-06 | 2 | 77 | 2 | 34438105 | ||
| Pubmed | MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. | 4.84e-06 | 2 | 77 | 2 | 10615123 | |
| Interaction | CYP2C19 interactions | 4.92e-07 | 5 | 75 | 3 | int:CYP2C19 | |
| Interaction | NAT8B interactions | 1.01e-06 | 21 | 75 | 4 | int:NAT8B | |
| Interaction | CYP2C18 interactions | 2.91e-06 | 27 | 75 | 4 | int:CYP2C18 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr10q23 | 2.02e-05 | 195 | 77 | 5 | chr10q23 | |
| Cytoband | 10q24 | 2.86e-05 | 35 | 77 | 3 | 10q24 | |
| Cytoband | 1q25 | 8.79e-04 | 26 | 77 | 2 | 1q25 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2p13 | 1.72e-03 | 140 | 77 | 3 | chr2p13 | |
| GeneFamily | Cytochrome P450 family 2 | 3.22e-06 | 35 | 53 | 4 | 1001 | |
| GeneFamily | MutL homologs | 5.04e-05 | 4 | 53 | 2 | 1027 | |
| GeneFamily | ADAM metallopeptidase domain containing|CD molecules | 9.97e-04 | 394 | 53 | 6 | 471 | |
| GeneFamily | RNA binding motif containing | 3.49e-03 | 213 | 53 | 4 | 725 | |
| Coexpression | CAIRO_HEPATOBLASTOMA_DN | 1.26e-05 | 267 | 76 | 7 | M13449 | |
| Coexpression | GSE3982_EOSINOPHIL_VS_TH2_DN | 2.43e-05 | 198 | 76 | 6 | M5425 | |
| Coexpression | GSE13306_RA_VS_UNTREATED_TCONV_UP | 2.57e-05 | 200 | 76 | 6 | M3234 | |
| Coexpression | GSE27859_DC_VS_CD11C_INT_F480_HI_MACROPHAGE_UP | 2.57e-05 | 200 | 76 | 6 | M8597 | |
| Coexpression | GSE18893_CTRL_VS_TNF_TREATED_TCONV_24H_UP | 2.57e-05 | 200 | 76 | 6 | M7304 | |
| Coexpression | SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN | 2.58e-05 | 20 | 76 | 3 | MM1104 | |
| CoexpressionAtlas | Myeloid Cells, DC.11cloSer.Salm3.SI, CD45+ MHCII+ Gr1- CD11c-lo CD11b+, Small Intestine, avg-4 | 4.28e-05 | 364 | 75 | 8 | GSM854276_500 | |
| CoexpressionAtlas | Myeloid Cells, DC.103-11b+.Salm3.SI, CD45+ MHCII+ Gr1- CD11c-hi CD11b+ CD103- F480+, Small Intestine, avg-4 | 4.63e-05 | 368 | 75 | 8 | GSM854258_500 | |
| CoexpressionAtlas | Myeloid Cells, DC.11cloSer.SI, CD45+ MHCII+ CD11c-lo CD11b+, Small Intestine, avg-5 | 5.48e-05 | 377 | 75 | 8 | GSM854280_500 | |
| CoexpressionAtlas | Myeloid Cells, DC.103-11b+.Lv, CD45+ CD11c+ MHC-II + CD11b high CD103-, Liver, avg-3 | 1.00e-04 | 411 | 75 | 8 | GSM538239_500 | |
| CoexpressionAtlas | B cells, proB.FrA.FL, CD19- IgM- CD43+ CD24intermediate AA4.1+ CD45R+ CD, Fetal Liver, avg-2 | 1.20e-04 | 422 | 75 | 8 | GSM538355_500 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Hematopoietic-Myeloid-LYVE1+_Macrophage|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.01e-06 | 194 | 76 | 6 | ad72be9f6871b334e1f477d868c15e7792fadea5 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid-LYVE1+_Macrophage|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.04e-06 | 195 | 76 | 6 | c16479a10f5ca2e89aea1742dbc5cc4dc9f3ea88 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid-MMP9+_Inflammatory_macrophage|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.04e-06 | 195 | 76 | 6 | 5a7c74f96f213c504abd65e751800da7e03e47d9 | |
| ToppCell | distal-1-Hematologic-Interstitial_Macrophage|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.11e-06 | 197 | 76 | 6 | 9e5df74aeeefa4d928ec07c036aacb549c797f30 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Degenerative_Outer_Medullary_Collecting_Duct_Principal_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.14e-06 | 198 | 76 | 6 | 0d9d401190792fd61434f1b82548253187d805f0 | |
| ToppCell | BAL-Control-cDC_0|Control / Compartment, Disease Groups and Clusters | 1.17e-06 | 199 | 76 | 6 | 4518ffa51ead9da1ddf07bf048b18602e50f0f84 | |
| ToppCell | tumor_Lung-Myeloid_cells-mo-Mac|Myeloid_cells / Location, Cell class and cell subclass | 1.21e-06 | 200 | 76 | 6 | 58ff8db0ecf71daa86f9a38208e0d9b712cac0b5 | |
| ToppCell | Sigmoid-Macrophage-Macrophage|Sigmoid / Region, Cell class and subclass | 1.21e-06 | 200 | 76 | 6 | 9ee3a799de7bade1bfe94b6827461633f02bc1dc | |
| ToppCell | tumor_Lymph_Node_/_Brain-Myeloid_cells-mo-Mac|Myeloid_cells / Location, Cell class and cell subclass | 1.21e-06 | 200 | 76 | 6 | 195862a319794e57f0506757ae45ab70200bc5b4 | |
| ToppCell | Sigmoid-(6)_Macrophage-(60)_Macrophage|Sigmoid / shred on region, Cell_type, and subtype | 1.21e-06 | 200 | 76 | 6 | ad84a83a5a1893f7b053d39eddeca851463a8ff0 | |
| ToppCell | TCGA-Bile_Duct|World / Sample_Type by Project: Shred V9 | 4.20e-06 | 140 | 76 | 5 | ca8a0ccbc2f501b759864fe9bb06dc8b44b6b31f | |
| ToppCell | BAL-Severe-Myeloid-cDC-cDC-cDC_6|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 7.12e-06 | 156 | 76 | 5 | 0f2147abcf31a26ee5b2f4d8c5d72232612a33f0 | |
| ToppCell | BAL-Severe-Myeloid-cDC-cDC-cDC_6|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.12e-06 | 156 | 76 | 5 | cb87f12443fdc5538b856f765fcbac9406044e10 | |
| ToppCell | tumor_Lymph_Node_/_Brain-Myeloid_cells-CD1c+_DCs|Myeloid_cells / Location, Cell class and cell subclass | 7.81e-06 | 159 | 76 | 5 | b3c52908cd24bbf851fac69db3850fc7f53c2092 | |
| ToppCell | (6)_Macrophage-(60)_Macrophage|(6)_Macrophage / shred on Cell_type and subtype | 7.91e-06 | 74 | 76 | 4 | 356978d2ee61e7042d7a9ad3bc744d3e7a7f76c0 | |
| ToppCell | normal_Lymph_Node-Myeloid_cells-CD141+_DCs|Myeloid_cells / Location, Cell class and cell subclass | 9.62e-06 | 166 | 76 | 5 | 6210a136efb99d70c2026b6454363f1bd2723558 | |
| ToppCell | 356C-Myeloid-Dendritic-cDC1|356C / Donor, Lineage, Cell class and subclass (all cells) | 9.62e-06 | 166 | 76 | 5 | 0590e404f45afce90e20f93f90a3def83949c66b | |
| ToppCell | Sigmoid-Macrophage-Macrophage|Macrophage / Region, Cell class and subclass | 1.02e-05 | 168 | 76 | 5 | bb16e135b6ae0d66615420b61edd6f62f2a3233c | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_DC-DC-DC1|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.05e-05 | 169 | 76 | 5 | 488ba50631a64cb9e0d69219491c66ac824c9e7d | |
| ToppCell | facs-Marrow-KLS-18m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.14e-05 | 172 | 76 | 5 | 979fd7b435f59b8a4d290a809cf76147d4c63d48 | |
| ToppCell | facs-Marrow-KLS-18m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.14e-05 | 172 | 76 | 5 | f4d7f416802218ce56408fa4cb8a555d846bc85b | |
| ToppCell | 5'-Adult-LargeIntestine-Hematopoietic-Myeloid-cDC1|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.18e-05 | 173 | 76 | 5 | d13ae4046a25ee0fb492ddedf44583a879a432e9 | |
| ToppCell | Leuk-UTI-Myeloid-cDC1|Leuk-UTI / Disease, Lineage and Cell Type | 1.18e-05 | 173 | 76 | 5 | 226bb8d881f32d65c60f5e4c034c6d465f8e7ba5 | |
| ToppCell | COVID-mDC1-|COVID / Condition, Cell_class and T cell subcluster | 1.24e-05 | 175 | 76 | 5 | 83a95d6fc2ddf3ec53f05825bbc982fb8d2ccd15 | |
| ToppCell | COVID-mDC1|COVID / Condition, Cell_class and T cell subcluster | 1.24e-05 | 175 | 76 | 5 | b9280444016e21c28131a61df65cc5c56d402412 | |
| ToppCell | systemic_lupus_erythematosus-flare-Myeloid-conventional_dendritic_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.24e-05 | 175 | 76 | 5 | c58a1f02d1e559d3638fe1500e960e82a8a7187b | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-Myeloid-cDC2|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.31e-05 | 177 | 76 | 5 | 23c1bce4ae3b94f56263f5a9f6bbd1805c097a12 | |
| ToppCell | normal_Lymph_Node-Myeloid_cells-CD141+_DCs|normal_Lymph_Node / Location, Cell class and cell subclass | 1.39e-05 | 179 | 76 | 5 | ec995ccd6e1dbd06287ad836c232d9aed1cf94a8 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_MHC-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.67e-05 | 186 | 76 | 5 | c7e2134454ab5d0885050dd1bb3c3bd15bf497ac | |
| ToppCell | (7)_DC_1|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 1.75e-05 | 188 | 76 | 5 | 832887afa4a54ed80906bc02176d646529c13398 | |
| ToppCell | droplet-Tongue-nan|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.75e-05 | 188 | 76 | 5 | d62cc37e86b7b186e53aeb7f421c4e5ee28f23bd | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-D|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.75e-05 | 188 | 76 | 5 | 5f6ad5d693145d846ca561c2fa55465a88e40b90 | |
| ToppCell | BAL-Severe-Myeloid-cDC-cDC-cDC_0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.75e-05 | 188 | 76 | 5 | 9fc3819aae5a2b2534cb131d467435b5cfc420d6 | |
| ToppCell | BAL-Severe-Myeloid-cDC-cDC-cDC_0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.75e-05 | 188 | 76 | 5 | 5e5d779ea079d3b2a1ef650b06b9f5cc1ffef5e7 | |
| ToppCell | COVID-19-Myeloid-DC1|Myeloid / Condition, Lineage and Cell class | 1.89e-05 | 191 | 76 | 5 | 4be3c6287965fe3a2f109d26f68bdc2fa393f99b | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.99e-05 | 193 | 76 | 5 | c7e9e6e4bf5e07c9cbdf1aa7c8828f4b2500e3ff | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Inner_Medullary_Collecting_Duct_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.99e-05 | 193 | 76 | 5 | a5695ce2e24a62026ae28f3dea07ca4a435206b8 | |
| ToppCell | 3'-Child09-12-SmallIntestine-Hematopoietic-Myeloid-LYVE1+_Macrophage|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.04e-05 | 194 | 76 | 5 | 8e2819a9d0529f7b2de1a7c1190575175d6173ee | |
| ToppCell | (7)_MNP-(7)_DC_1|(7)_MNP / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 2.04e-05 | 194 | 76 | 5 | 8dbe0188e2af6f14b3b44e5213fbdd581128082f | |
| ToppCell | ILEUM-inflamed-(3)_moDC|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.04e-05 | 194 | 76 | 5 | c9d2acab0bbcfa9a9113cf3b9f8147403f0beb43 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.09e-05 | 195 | 76 | 5 | 3d6d3de8ada6dce3dc789c15b50cc066e7100496 | |
| ToppCell | Tracheal-NucSeq-Immune_Myeloid-Dendritic_cell-DC_1|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.14e-05 | 196 | 76 | 5 | b71d711be5609115b00a57700885aca608920896 | |
| ToppCell | PBMC-Control-Myeloid-cDC|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.14e-05 | 196 | 76 | 5 | e1f763fa9c11bf5f4d80e79f70f9485724ac23fe | |
| ToppCell | 10x5'-GI_small-bowel-Myeloid_Mac-Intestinal_macrophages|GI_small-bowel / Manually curated celltypes from each tissue | 2.14e-05 | 196 | 76 | 5 | 075e5746fa5cb121115a1d51b823c0fbf8d54305 | |
| ToppCell | Control-Myeloid-cDC|Control / Disease group, lineage and cell class | 2.14e-05 | 196 | 76 | 5 | 85d92bc226cc28384c30991cc4ebb02ec2e3ec99 | |
| ToppCell | PBMC-Control-Myeloid-cDC-cDC|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.14e-05 | 196 | 76 | 5 | 553c22c7d48f3b4f6f2b2f10d6e668c5ebb09e8c | |
| ToppCell | PBMC-Control-Myeloid-cDC|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.14e-05 | 196 | 76 | 5 | d376168e15ec1cf618723259966c76be3698b9b0 | |
| ToppCell | critical-Epithelial-Secretory|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.14e-05 | 196 | 76 | 5 | dbf14f5851c2b779a8b35e820c4584ea9096e49d | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_macrophage-stroma-stromal_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.14e-05 | 196 | 76 | 5 | 88517bb92be2f05c1e1ad94af22ac10d8c5c13c7 | |
| ToppCell | PBMC-Control-Myeloid-cDC-cDC|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.14e-05 | 196 | 76 | 5 | 4a9095ba3f6709f88f32bf09184553f4bd211f43 | |
| ToppCell | 10x5'-GI_small-bowel-Myeloid_Mac-Erythrophagocytic_macrophages|GI_small-bowel / Manually curated celltypes from each tissue | 2.20e-05 | 197 | 76 | 5 | be9879e3352b8c17e91ab1e2d1fb4c30ef6d8ce8 | |
| ToppCell | 343B-Myeloid-Dendritic|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 2.20e-05 | 197 | 76 | 5 | b340d6f041231e5c69140895aaa1e8d28bafb998 | |
| ToppCell | 5'-Adult-LargeIntestine-Hematopoietic-Myeloid-Macrophages|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.20e-05 | 197 | 76 | 5 | e698a0bbb20bd4868ff4348f2ac9f609942b55fa | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.20e-05 | 197 | 76 | 5 | 769a4203c014b34d16d4d76d3caf07ddb2c41abc | |
| ToppCell | URO-Myeloid-cDC2|URO / Disease, Lineage and Cell Type | 2.20e-05 | 197 | 76 | 5 | 7fee14356d7fba68a0515c8b9284568d14124b0a | |
| ToppCell | 10x5'v1-week_12-13-Myeloid_macrophage-stroma-stromal_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.20e-05 | 197 | 76 | 5 | 075044c17f1c52008cd3c292c15cbf485b50411e | |
| ToppCell | 390C-Myeloid-Dendritic|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.20e-05 | 197 | 76 | 5 | 424526c94b9a73c1c28ddc65dfba53aba5c6b2d2 | |
| ToppCell | Healthy-cDC|World / disease group, cell group and cell class | 2.25e-05 | 198 | 76 | 5 | 8976f8d26cb7ff79f74def138c4bbbb0bc2eaf00 | |
| ToppCell | severe-HLA-DR+_CD83+_Monocyte|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.25e-05 | 198 | 76 | 5 | a77f3440d7fb6a50066abc7e9ad59e83798ef13d | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.25e-05 | 198 | 76 | 5 | eb0a94c426a7c567f94490b848e28784587c6dcd | |
| ToppCell | BAL-Control-Myeloid-cDC-cDC-cDC_0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.25e-05 | 198 | 76 | 5 | 59214e34b077dffa989c48635fdef143f57f1320 | |
| ToppCell | distal-Hematologic-Interstitial_Macrophage|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 2.25e-05 | 198 | 76 | 5 | a35b43d38e18c6f8f0cd9015b8e23f71c729f023 | |
| ToppCell | BAL-Control-Myeloid-cDC-cDC-cDC_0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.25e-05 | 198 | 76 | 5 | 7f7024b26337ae2bc7f57c3274a7dfdaaa64ab7c | |
| ToppCell | moderate-Epithelial-Secretory|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.25e-05 | 198 | 76 | 5 | 7ecce5e266bb08797088cc8f8309e0c7b48df5c9 | |
| ToppCell | 10x5'-GI_small-bowel-Myeloid_Mac|GI_small-bowel / Manually curated celltypes from each tissue | 2.25e-05 | 198 | 76 | 5 | 748db69d3c9774e44c0cc425d937d18b83af8312 | |
| ToppCell | myeloid-Dendritic_cell-Conventional_dendritic_cell|World / Lineage, cell class and subclass | 2.25e-05 | 198 | 76 | 5 | 2ec42643200aa9feb33e2b87570f276fbad21cad | |
| ToppCell | Healthy-cDC|Healthy / disease group, cell group and cell class | 2.25e-05 | 198 | 76 | 5 | 4cf874333b9fd6cd22ee647cd12c032fc6d05740 | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Monocytic-Classical_monocytes|lymph-node_spleen / Manually curated celltypes from each tissue | 2.25e-05 | 198 | 76 | 5 | 187a04d498f0b355cb11c81172721698818082d6 | |
| ToppCell | myeloid-Dendritic_cell|World / Lineage, cell class and subclass | 2.25e-05 | 198 | 76 | 5 | 240fff8264caeb7d1efcbccb187fe93744559bbc | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Monocytic|lymph-node_spleen / Manually curated celltypes from each tissue | 2.25e-05 | 198 | 76 | 5 | 065c8a9655d19f93dfdb453c78bbfe7d857caf3e | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_macrophage-stroma-stromal_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.30e-05 | 199 | 76 | 5 | 2649afa3ccda78e9d1df26127b66cbfa0c6cd01d | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.30e-05 | 199 | 76 | 5 | 980b10b81ee9dc952e3be25bd294201ce5a4ca8b | |
| ToppCell | Bronchial-10x5prime-Immune_Myeloid-Dendritic_cell-DC_2|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.30e-05 | 199 | 76 | 5 | fdd8c4c04837341e17a4772a2adcdf2f187c56b1 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Hematopoietic-Myeloid|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.30e-05 | 199 | 76 | 5 | c684530d4d8073337379c2a24e5e54297fb13691 | |
| ToppCell | NS-control-d_0-4-Epithelial-Secretory|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.30e-05 | 199 | 76 | 5 | 32bdfff40fd442b88489c8b0f79af3927a51a03c | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_macrophage-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.30e-05 | 199 | 76 | 5 | cbd423c31d75f6d2f5ae85d2241641fcbe630b81 | |
| ToppCell | control-Epithelial-Secretory|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.30e-05 | 199 | 76 | 5 | 3d01f90ffd271ca00129192787e4921bdca7e01e | |
| ToppCell | control-Epithelial-Secretory|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.30e-05 | 199 | 76 | 5 | 262e5b8a52c8ddb0b47048c786e8bdb7158e1b9a | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_macrophage-macrophage|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.36e-05 | 200 | 76 | 5 | bc56d6d6d32405685e9bd553ebdbe48b8fbe6902 | |
| ToppCell | Parenchyma_Control_(B.)-Immune-TX-MoAM-1|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 2.36e-05 | 200 | 76 | 5 | 59b2ebb69699c9bebf8c2697eb678fdccd0a998c | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.36e-05 | 200 | 76 | 5 | 2cca77b2c9d829daa674a844e068f2b083e90d6e | |
| ToppCell | Control-Control-Myeloid-cDC|Control / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | 1375d199320feb85ba06e74b10df6521e790addf | |
| ToppCell | Lung_Parenchyma-Control-Myeloid-MoAM-MoAM-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.36e-05 | 200 | 76 | 5 | 390f9429feae991b8524e2815d8fcd4914c74459 | |
| ToppCell | mild-HLA-DR-_S100A+_Monocyte|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.36e-05 | 200 | 76 | 5 | 6dd89835a9f7bebb4849cff8eecb82caf6e1acbf | |
| ToppCell | control-cDC|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.36e-05 | 200 | 76 | 5 | 4a6d17a4225be38537d3dd8a39512051f597f4e0 | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_macrophage|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.36e-05 | 200 | 76 | 5 | d08c0b10cd95bfb462792e368627b3e36582b263 | |
| ToppCell | Severe-Myeloid-Macrophages-FCN1-SPP1+|Severe / Condition, Lineage, Cell class and cell subclass | 2.36e-05 | 200 | 76 | 5 | b8cd209b810312793465b28bb2a6cbe5d94da91f | |
| ToppCell | mild-HLA-DR+_CD83+_Monocyte|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.36e-05 | 200 | 76 | 5 | 8a480f487b52938d00b53bf4b18f067353d34419 | |
| ToppCell | Sepsis-Leuk-UTI-Myeloid-cDC1|Leuk-UTI / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | 186852d54eced4c036876cc891773605068b56b5 | |
| ToppCell | Control-Control-Myeloid-cDC1|Control / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | 86db36c9f9316bfa4d8fa26c5a8239fd2d7d34c2 | |
| ToppCell | Lung_Parenchyma-Control-Myeloid-MoAM-MoAM|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.36e-05 | 200 | 76 | 5 | f7e9b4a8ededb116774528b38ea3381b6f05915c | |
| ToppCell | COVID-19-Myeloid-MoAM2,_CCL18|COVID-19 / Condition, Lineage and Cell class | 2.36e-05 | 200 | 76 | 5 | b0a50622d00335843efad86bc56a1e910019984b | |
| ToppCell | Sepsis-URO-Myeloid-cDC2|URO / Disease, condition lineage and cell class | 2.36e-05 | 200 | 76 | 5 | 4f696dc68a8ceec9a6e6293c6f6f878b321b0b6d | |
| ToppCell | Lung_Parenchyma-Control-Myeloid-MoAM|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.36e-05 | 200 | 76 | 5 | d98c523ac0e4767aaeef50cae142513d115212ab | |
| ToppCell | TCGA-Thymus-Primary_Tumor-Thymoma-Type_B3-5|TCGA-Thymus / Sample_Type by Project: Shred V9 | 5.32e-05 | 120 | 76 | 4 | 9d4e630e1d3b9adf94a1884071bfe46edaa3f0c1 | |
| ToppCell | LPS-antiTNF-Myeloid-Dendritic_cells-Monocytes-Macrophages|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.84e-05 | 128 | 76 | 4 | cfc73cb803ba50a4a8709e19e70e1e399118c849 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Undifferentiated_Pleomorphic_Sarcoma-4|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 7.49e-05 | 131 | 76 | 4 | 2ccf679b5035b7b9cdb9a9a660cad90288592187 | |
| ToppCell | facs-Aorta-Heart-3m-Myeloid-nan|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.42e-05 | 139 | 76 | 4 | 22a769d5195ed761ef333ef542746e1ba617a698 | |
| ToppCell | facs-Aorta-Heart-3m-Myeloid-professional_antigen_presenting_cell|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.42e-05 | 139 | 76 | 4 | 292533e04178dd36d57377562077f9deb2cb9746 | |
| ToppCell | E16.5-samps-Mesenchymal-Myofibroblast-Smooth_Muscle-like_MyoFibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass | 9.68e-05 | 140 | 76 | 4 | 5623a0a68403fc00166b7d13d13e184a718d9bdd | |
| Computational | Cytochrome P450. | 3.11e-07 | 14 | 47 | 4 | MODULE_106 | |
| Computational | Genes in the cancer module 135. | 1.68e-04 | 25 | 47 | 3 | MODULE_135 | |
| Computational | Neighborhood of IGF1 | 1.90e-04 | 26 | 47 | 3 | GNF2_IGF1 | |
| Drug | 4',5-dihydroxydiclofenac | 1.71e-09 | 6 | 76 | 4 | CID003052567 | |
| Drug | 3'-hydroxydiclofenac | 1.71e-09 | 6 | 76 | 4 | CID000112230 | |
| Drug | D 703 | 3.00e-09 | 18 | 76 | 5 | CID000054088 | |
| Drug | 1,4-naphthoquinone | 2.26e-08 | 26 | 76 | 5 | ctd:C035342 | |
| Drug | 5-hydroxydiclofenac | 5.56e-08 | 12 | 76 | 4 | CID003052566 | |
| Drug | methysticin | 1.43e-07 | 4 | 76 | 3 | ctd:C076881 | |
| Drug | 7,8-dihydromethysticin | 1.43e-07 | 4 | 76 | 3 | ctd:C107882 | |
| Drug | 2'-(glutathion-S-yl)-deschlorodiclofenac | 1.52e-07 | 15 | 76 | 4 | ctd:C586542 | |
| Drug | 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane | 2.02e-07 | 16 | 76 | 4 | ctd:C495657 | |
| Drug | furafylline | 2.47e-07 | 41 | 76 | 5 | CID000003433 | |
| Drug | Azamulinum | 3.39e-07 | 18 | 76 | 4 | CID003086060 | |
| Drug | 7-benzyloxyquinoline | 3.39e-07 | 18 | 76 | 4 | CID003035604 | |
| Drug | bufuralol | 3.56e-07 | 5 | 76 | 3 | ctd:C010831 | |
| Drug | polybrominated biphenyl | 3.56e-07 | 44 | 76 | 5 | CID000042948 | |
| Drug | hydroxytolbutamide | 4.28e-07 | 19 | 76 | 4 | CID000003656 | |
| Drug | D 617 | 4.28e-07 | 19 | 76 | 4 | CID000093168 | |
| Drug | 3C etc | 5.33e-07 | 20 | 76 | 4 | CID000164045 | |
| Drug | olivacine | 5.33e-07 | 20 | 76 | 4 | CID005281407 | |
| Drug | 19-HETE | 6.17e-07 | 49 | 76 | 5 | CID006439528 | |
| Drug | AC1L21VM | 6.57e-07 | 21 | 76 | 4 | CID000039524 | |
| Drug | 4,4'-cyclohexylidenebisphenol | 7.10e-07 | 6 | 76 | 3 | ctd:C570106 | |
| Drug | AC1O5Z5L | 7.10e-07 | 6 | 76 | 3 | CID006443527 | |
| Drug | Micotil | 7.65e-07 | 152 | 76 | 7 | CID000017675 | |
| Drug | 9-hydroxybenzo(a)pyrene | 9.18e-07 | 53 | 76 | 5 | CID000028598 | |
| Drug | triazolam | 1.01e-06 | 54 | 76 | 5 | CID000005556 | |
| Drug | 16-O-demethylaconitine | 1.24e-06 | 7 | 76 | 3 | ctd:C486136 | |
| Drug | 5-fluorotryptamine | 1.24e-06 | 7 | 76 | 3 | ctd:C034536 | |
| Drug | 6-Fluoro-6-desoxyoxymorphone | 1.24e-06 | 7 | 76 | 3 | CID005486899 | |
| Drug | 1,2-dihydroxynaphthalene | 1.33e-06 | 57 | 76 | 5 | CID000011318 | |
| Drug | Tolbutamide | 1.37e-06 | 25 | 76 | 4 | ctd:D014044 | |
| Drug | licochalcone A | 1.90e-06 | 27 | 76 | 4 | ctd:C070840 | |
| Drug | 7-ethoxy-4-trifluoromethylcoumarin | 1.90e-06 | 27 | 76 | 4 | CID000130779 | |
| Drug | 13-hydroxyeicosatetraenoic acid | 1.98e-06 | 8 | 76 | 3 | CID006439499 | |
| Drug | 11-HODE | 1.98e-06 | 8 | 76 | 3 | CID006438497 | |
| Drug | 5-bromotryptamine | 1.98e-06 | 8 | 76 | 3 | ctd:C040997 | |
| Drug | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | 1.98e-06 | 8 | 76 | 3 | ctd:C585955 | |
| Drug | seratrodast | 2.21e-06 | 28 | 76 | 4 | CID000002449 | |
| Drug | norverapamil | 2.21e-06 | 28 | 76 | 4 | CID000104972 | |
| Drug | (hydrochloride) | 2.56e-06 | 29 | 76 | 4 | CID000004923 | |
| Drug | 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide | 2.96e-06 | 9 | 76 | 3 | ctd:C545880 | |
| Drug | Acenocoumarol | 2.96e-06 | 9 | 76 | 3 | ctd:D000074 | |
| Drug | Tryptamines | 2.96e-06 | 9 | 76 | 3 | ctd:D014363 | |
| Drug | 5-chlorotryptamine | 2.96e-06 | 9 | 76 | 3 | ctd:C529169 | |
| Drug | 3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate | 2.96e-06 | 9 | 76 | 3 | ctd:C109602 | |
| Drug | 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid | 2.96e-06 | 9 | 76 | 3 | ctd:C000588958 | |
| Drug | piperonyl butoxide | 2.98e-06 | 67 | 76 | 5 | CID000005794 | |
| Drug | paliperidone | 3.37e-06 | 31 | 76 | 4 | CID000115237 | |
| Drug | 8(9)-EET | 3.45e-06 | 69 | 76 | 5 | CID000001901 | |
| Drug | BP-7,8-oxide | 3.84e-06 | 32 | 76 | 4 | CID000037455 | |
| Drug | DMEs | 3.98e-06 | 71 | 76 | 5 | CID003038361 | |
| Drug | norketobemidone | 4.22e-06 | 10 | 76 | 3 | CID000161154 | |
| Drug | sitaxsentan | 4.22e-06 | 10 | 76 | 3 | ctd:C106276 | |
| Drug | 1-naphthol | 4.36e-06 | 33 | 76 | 4 | ctd:C029350 | |
| Drug | Haloperidol metabolite I | 5.79e-06 | 11 | 76 | 3 | CID000038282 | |
| Drug | trans-1,2-dihydro-1,2-naphthalenediol | 5.79e-06 | 11 | 76 | 3 | ctd:C507866 | |
| Drug | BP-7,8-diol | 6.33e-06 | 78 | 76 | 5 | CID000025892 | |
| Drug | AC1L3O4Q | 6.96e-06 | 37 | 76 | 4 | CID000119057 | |
| Drug | 4-(N-propionylanilino)piperidine | 7.69e-06 | 12 | 76 | 3 | CID000259381 | |
| Drug | carveol | 7.69e-06 | 12 | 76 | 3 | CID000007438 | |
| Drug | desethylamodiaquine | 7.69e-06 | 12 | 76 | 3 | ctd:C047386 | |
| Drug | norclozapine | 7.69e-06 | 12 | 76 | 3 | ctd:C058272 | |
| Drug | nanofin | 8.63e-06 | 39 | 76 | 4 | CID000068843 | |
| Drug | Indoles | 8.63e-06 | 39 | 76 | 4 | ctd:D007211 | |
| Drug | Nicardipine | 8.63e-06 | 39 | 76 | 4 | ctd:D009529 | |
| Drug | emend | 9.56e-06 | 40 | 76 | 4 | CID000151165 | |
| Drug | diosmetin | 9.66e-06 | 85 | 76 | 5 | CID005281612 | |
| Drug | AC1L18GM | 9.98e-06 | 13 | 76 | 3 | CID000000092 | |
| Drug | 11,12-epoxy-5,8,14-eicosatrienoic acid | 9.98e-06 | 13 | 76 | 3 | ctd:C046783 | |
| Drug | 7-hydroxyquinoline | 9.98e-06 | 13 | 76 | 3 | CID000011378 | |
| Drug | 1'-hydroxymidazolam | 9.98e-06 | 13 | 76 | 3 | CID000107917 | |
| Drug | clozapine N-oxide | 9.98e-06 | 13 | 76 | 3 | CID000036727 | |
| Drug | 7-ethoxycoumarin | 1.02e-05 | 86 | 76 | 5 | CID000035703 | |
| Drug | dibenzylfluorescein | 1.10e-05 | 2 | 76 | 2 | ctd:C558664 | |
| Drug | L 654969 | 1.17e-05 | 42 | 76 | 4 | CID000005218 | |
| Drug | propionanilide | 1.27e-05 | 14 | 76 | 3 | CID000012107 | |
| Drug | 5-MeO-DIPT | 1.27e-05 | 14 | 76 | 3 | CID000151182 | |
| Drug | S-7HNa | 1.27e-05 | 14 | 76 | 3 | CID000188208 | |
| Drug | AC1L1J6H | 1.40e-05 | 236 | 76 | 7 | CID000004889 | |
| Drug | Methoxychlor | CYP2C19 CYP2C8 CYP2C9 CYP2C18 PSMA2 AHR ELAVL2 MMP14 TIPARP DHX9 | 1.40e-05 | 549 | 76 | 10 | ctd:D008731 |
| Drug | sulfaphenazole | 1.41e-05 | 44 | 76 | 4 | CID000005335 | |
| Drug | 4-hydroxymephenytoin | 1.58e-05 | 15 | 76 | 3 | CID000119507 | |
| Drug | ethoxyresorufin | 1.66e-05 | 95 | 76 | 5 | CID000003294 | |
| Drug | Chlorpromazine | CYP2C19 CYP2C8 CYP2C9 CYP2C18 ASAH1 ABCB5 AHR DPP3 LEPR TIPARP | 1.77e-05 | 564 | 76 | 10 | ctd:D002746 |
| Drug | Ifosfamide | 1.93e-05 | 248 | 76 | 7 | ctd:D007069 | |
| Drug | propafenone | 1.93e-05 | 98 | 76 | 5 | CID000004932 | |
| Drug | PCB 77 | 1.93e-05 | 98 | 76 | 5 | CID000036187 | |
| Drug | 4,4'-(hexafluoroisopropylidene)diphenol | 1.94e-05 | 16 | 76 | 3 | ctd:C571725 | |
| Drug | 6-hydroxychlorzoxazone | 1.94e-05 | 16 | 76 | 3 | CID000002734 | |
| Drug | Amodiaquine | 1.94e-05 | 16 | 76 | 3 | ctd:D000655 | |
| Drug | 1-phenylazo-2-naphthol | 1.94e-05 | 16 | 76 | 3 | ctd:C024336 | |
| Drug | 2cgu | 2.00e-05 | 48 | 76 | 4 | CID003506204 | |
| Drug | AC1L1KIN | 2.13e-05 | 100 | 76 | 5 | CID000005516 | |
| Drug | felodipine | 2.18e-05 | 169 | 76 | 6 | CID000003333 | |
| Drug | omeprazole | 2.24e-05 | 101 | 76 | 5 | CID000004594 | |
| Drug | 4-vinyl-1-cyclohexene dioxide | 2.25e-05 | 170 | 76 | 6 | ctd:C012606 | |
| Drug | 6-hydroxymelatonin | 2.35e-05 | 50 | 76 | 4 | CID000001864 | |
| Drug | diosmetin | 2.35e-05 | 17 | 76 | 3 | ctd:C039602 | |
| Drug | K-K-K | 2.65e-05 | 175 | 76 | 6 | CID000003823 | |
| Drug | N-desmethyl-tamoxifen-hydrochloride | 2.75e-05 | 52 | 76 | 4 | CID000035887 | |
| Drug | pleuromutilin | 2.81e-05 | 18 | 76 | 3 | CID000031326 | |
| Disease | X-21258 measurement | 1.51e-08 | 3 | 74 | 3 | EFO_0800802 | |
| Disease | S-6-hydroxywarfarin to S-warfarin ratio measurement | 2.88e-06 | 88 | 74 | 5 | EFO_0803332 | |
| Disease | X-14473 measurement | 6.20e-06 | 2 | 74 | 2 | EFO_0021370 | |
| Disease | cyclo(leu-pro) measurement | 1.86e-05 | 3 | 74 | 2 | EFO_0800676 | |
| Disease | Colorectal Carcinoma | 6.46e-05 | 702 | 74 | 9 | C0009402 | |
| Disease | hepatocellular carcinoma (is_implicated_in) | 9.40e-05 | 181 | 74 | 5 | DOID:684 (is_implicated_in) | |
| Disease | S-warfarin to R-warfarin ratio measurement | 9.76e-05 | 95 | 74 | 4 | EFO_0803331 | |
| Disease | glycine conjugate of C10H14O2 (1) measurement | 1.29e-04 | 7 | 74 | 2 | EFO_0800655 | |
| Disease | response to anticoagulant | 1.51e-04 | 41 | 74 | 3 | GO_0061476 | |
| Disease | Malignant neoplasm of prostate | 1.55e-04 | 616 | 74 | 8 | C0376358 | |
| Disease | X-11787 measurement | 1.72e-04 | 8 | 74 | 2 | EFO_0021258 | |
| Disease | Lynch Syndrome | 2.21e-04 | 9 | 74 | 2 | C4552100 | |
| Disease | plasma clozapine-to-N-desmethylclozapine ratio measurement | 2.21e-04 | 9 | 74 | 2 | EFO_0600040 | |
| Disease | X-11308 measurement | 3.36e-04 | 11 | 74 | 2 | EFO_0800693 | |
| Disease | Malignant neoplasm of breast | 3.40e-04 | 1074 | 74 | 10 | C0006142 | |
| Disease | ecosanoids measurement | 3.62e-04 | 55 | 74 | 3 | EFO_0020044 | |
| Disease | rheumatoid arthritis (implicated_via_orthology) | 4.03e-04 | 12 | 74 | 2 | DOID:7148 (implicated_via_orthology) | |
| Disease | thymol sulfate measurement | 4.03e-04 | 12 | 74 | 2 | EFO_0021170 | |
| Disease | N-acetyl-2-aminooctanoate measurement | 4.03e-04 | 12 | 74 | 2 | EFO_0800567 | |
| Disease | metabolite measurement | 5.13e-04 | 560 | 74 | 7 | EFO_0004725 | |
| Disease | 16a-hydroxy DHEA 3-sulfate measurement | 6.38e-04 | 15 | 74 | 2 | EFO_0800301 | |
| Disease | Paroxysmal atrial fibrillation | 6.49e-04 | 156 | 74 | 4 | C0235480 | |
| Disease | familial atrial fibrillation | 6.49e-04 | 156 | 74 | 4 | C3468561 | |
| Disease | Persistent atrial fibrillation | 6.49e-04 | 156 | 74 | 4 | C2585653 | |
| Disease | Atrial Fibrillation | 7.13e-04 | 160 | 74 | 4 | C0004238 | |
| Disease | N-acetylarginine measurement | 7.28e-04 | 16 | 74 | 2 | EFO_0021429 | |
| Disease | andro steroid monosulfate C19H28O6S (1) measurement | 7.28e-04 | 16 | 74 | 2 | EFO_0800305 | |
| Disease | Prostatic Neoplasms | 8.97e-04 | 616 | 74 | 7 | C0033578 | |
| Disease | Hereditary Non-Polyposis Colon Cancer Type 2 | 1.03e-03 | 19 | 74 | 2 | C1333991 | |
| Disease | metabolonic lactone sulfate measurement | 1.03e-03 | 19 | 74 | 2 | EFO_0800659 | |
| Disease | coffee consumption measurement | 1.15e-03 | 182 | 74 | 4 | EFO_0006781 | |
| Disease | Neoplasm Invasiveness | 1.20e-03 | 184 | 74 | 4 | C0027626 | |
| Disease | Splenomegaly | 1.39e-03 | 22 | 74 | 2 | C0038002 | |
| Disease | platelet reactivity measurement, response to clopidogrel | 1.52e-03 | 23 | 74 | 2 | EFO_0004985, GO_1903493 | |
| Disease | Dyslipidemias | 1.65e-03 | 24 | 74 | 2 | C0242339 | |
| Disease | Dyslipoproteinemias | 1.65e-03 | 24 | 74 | 2 | C0598784 | |
| Disease | Lynch syndrome (is_implicated_in) | 1.65e-03 | 24 | 74 | 2 | DOID:3883 (is_implicated_in) | |
| Disease | Hereditary Nonpolyposis Colorectal Neoplasms | 1.94e-03 | 26 | 74 | 2 | C0009405 | |
| Disease | Hereditary non-polyposis colorectal cancer syndrome | 2.09e-03 | 27 | 74 | 2 | C1112155 | |
| Disease | Hereditary Nonpolyposis Colorectal Cancer | 2.41e-03 | 29 | 74 | 2 | C1333990 | |
| Disease | arteriosclerosis (is_marker_for) | 2.41e-03 | 29 | 74 | 2 | DOID:2349 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| SSGFLAMNFQGKLKY | 231 | P35869 | |
| TVKKYVYFQGTGDMN | 316 | Q9Y5B0 | |
| SMKAQYVAGNGFRKV | 716 | Q9UJX5 | |
| FQGVMQKYSSSLFKT | 86 | Q96Q27 | |
| ASKVSLGAVYFFMNG | 286 | Q2M3G0 | |
| NGNFKKSDYFMPFSA | 416 | P10632 | |
| TNKCKGFGFVTMTNY | 321 | Q14576 | |
| KTVFKASSFAGYVGM | 196 | Q13510 | |
| MRAFGKNNSYGKSLS | 451 | O94921 | |
| TAGALFYFNMGKLKQ | 101 | P27701 | |
| AAMQKFYGLQVTGKA | 66 | P50281 | |
| SFMDGYKQKNAYIGT | 361 | P43378 | |
| ATMFGQGSYFAKKAS | 556 | Q7Z3E1 | |
| YVSKMLGTGKLGFSF | 1131 | O60271 | |
| MVINTSGKYGYKSTF | 436 | Q17RR3 | |
| GKFKSGFPQVSMFFT | 506 | P04196 | |
| MSRQFTYKSGAAAKG | 1 | Q86Y46 | |
| MKTTSNFSGKGYIIQ | 236 | O60524 | |
| QKFMAYLSQGGKVLG | 231 | P50747 | |
| MKSYAGFLTVNKTYN | 71 | Q9H3G5 | |
| KMGQYKESFANAGFT | 926 | P29323 | |
| KLTFNITSGNYMGFF | 1171 | Q9NYQ8 | |
| FVAMSSKGKLYGSPF | 136 | P08620 | |
| YTMFSAFQEGSKKSQ | 691 | Q9UHC1 | |
| QYFVKKGMQDIFSAS | 766 | Q9H706 | |
| SGQMAQKFSFSKVFG | 106 | Q96Q89 | |
| SNMGNYKSFGDTKFV | 101 | Q9NY33 | |
| GTSSKKTFASYMPQF | 1131 | P48357 | |
| SPSYAKKFQGRFTMT | 76 | P0DTW3 | |
| YLSVRGGFNMSSFKL | 116 | P05162 | |
| NMGKFILTFSYGNHK | 476 | Q96M69 | |
| TNKCKGFGFVTMTNY | 281 | Q15717 | |
| LFATTGYPGKMASQF | 266 | Q8NFH4 | |
| LKNTSYKGFFQLMCS | 266 | Q86Y13 | |
| SNSKIYFGKDIPNMF | 291 | O94905 | |
| FMRKFKIGYSNNGSD | 511 | O14786 | |
| KIFQASGKKMGSYFG | 291 | Q13797 | |
| KCLQKMGSGLNSFYD | 581 | A6NKT7 | |
| FGKVMNATAYGISKT | 621 | P36888 | |
| GGNFKKSNYFMPFSA | 416 | P33261 | |
| SFPFAQFSKMGKQLT | 161 | O00115 | |
| TKKMGGKDFSFRYQQ | 401 | Q6DD88 | |
| MYYKFSGFTQKLAGA | 1 | O14548 | |
| FNTNKCKGFGFVTMT | 311 | Q12926 | |
| SVNYDTKSGPKNMTF | 51 | P11279 | |
| SGNFKKSDYFMPFSA | 416 | P33260 | |
| QYFKENGYVTMSVGK | 121 | P22304 | |
| MSKQYYSFKKGVGSG | 1 | Q8NDH2 | |
| GGNFKKSKYFMPFSA | 416 | P11712 | |
| FNIYKKDFGKMTANS | 431 | Q6SJ93 | |
| SLANKSITYQMFGKT | 931 | Q56UN5 | |
| EGYNYTGMGNSTNKK | 41 | Q08211 | |
| VGSTYNYLGKKTNQM | 216 | Q9BXD5 | |
| KCLQKMGSGLNSFYD | 581 | Q7Z3J3 | |
| DMKIFYKGKNTGSNA | 1006 | Q92673 | |
| TKGRKMTQQSFGYGT | 81 | Q4G0N0 | |
| QTLGNAKAFCGMKYS | 511 | Q9HB63 | |
| ATAFKYFSMAASKGN | 356 | Q5TEA6 | |
| FFDKKYSNMSTLGNN | 1426 | Q5QGS0 | |
| DFYGKSSHGNTMKQF | 201 | Q86UY8 | |
| GLSKYGMKNIVSAFG | 451 | Q96PZ0 | |
| GTKTSFYGFTVNTMK | 191 | Q9UJ37 | |
| KTLAFKMNGYISNAN | 236 | P40692 | |
| YKSGNIEKTFTGMQN | 1541 | Q13023 | |
| RNYSIMKFNEFNKGG | 86 | P17032 | |
| SGYFKMLLSQNSKET | 46 | Q96BR9 | |
| QKNKEYVSIASGGFM | 421 | Q9NUY8 | |
| TAMGKNYVNGKTFLE | 161 | P25787 | |
| GFLMTFLKKYGFSSV | 66 | Q02094 | |
| NFFAAITKMKTCGYG | 136 | Q2M238 | |
| LIAGGLFMFTYKSTQ | 146 | Q9NQQ7 | |
| NVGTAISKKFGDMSY | 116 | Q16890 | |
| SAKLYGSFNFRMKTS | 271 | Q96NL1 | |
| MNGAYFKQSSVFTKD | 376 | Q6N021 | |
| MATGKSKGYGFVSFF | 141 | P31483 | |
| QLSAMGLYQSLGFKK | 181 | Q9UHF3 | |
| ALYQSMGFKKTGQSF | 186 | Q9UHE5 |